Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.

NCT01990885 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Celiac Disease

Interventions

DRUG: BL-7010
DRUG: Placebo

Sponsor

BioLineRx, Ltd.